Articles tagged with Leukemia
Researchers developed a groundbreaking diagnostic tool called MARLIN to classify acute leukemia with speed and accuracy using DNA methylation patterns and machine learning. The tool demonstrates high accuracy for disease classification in under two hours from the time of biopsy, providing rapid insights into leukemia subtypes.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
A federally funded study found children with leukemia who were exposed to pesticides during their mother's pregnancy had a higher risk of death. The study, published in Cancers, examined over 800 children and showed pesticide exposure increased child mortality by up to 60%.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers have identified a previously unknown molecular mechanism behind chemoresistance in acute myeloid leukemia (AML), a type of blood cancer. The study found that a protein called RUNX1C plays a key role in this process, and blocking its activity with RNA-targeting tools can improve chemotherapy's effectiveness.
Researchers have identified a key synergistic role for two epigenetic markers involved in programming cell fate. Turning off these markers causes genes to over-activate, disrupting normal cell development. This discovery may indicate a new target for treating some types of leukemia with drugs already in clinical trials for other cancers.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Researchers discovered cancer cells can survive within bone marrow fibroblasts in response to BTK inhibitors, leading to higher survival rates. By blocking CXCR4, treatment may become more effective, potentially increasing complete response rates and moving toward a cure for cancer
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
Researchers from Kumamoto University identified a genetic 'silencer' element that keeps the human T-cell leukemia virus type 1 (HTLV-1) in a dormant state, evading immune detection. This discovery offers hope for new therapeutic approaches to treat HTLV-1 and potentially even HIV.
A study found that immunoglobulin replacement therapy was ineffective in reducing serious infections requiring hospitalization among CLL patients. Despite increasing use of the therapy, infection rates remained high, highlighting a need for better clinical guidelines and evaluation of treatment duration.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
A new study found that exercise can improve the quality of life and symptom management for CLL patients, but personalized guidance is needed. Patients prefer virtual classes, expert advice from cancer care specialists, and tailored programs addressing their unique challenges.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
The study found that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Researchers identified a 'multipotency score' to predict clinical outcomes, providing valuable insights into drug resistance and str...
Researchers at Weizmann Institute of Science develop innovative blood test to detect leukemia risk and diagnose age-related conditions like MDS. The test may replace invasive bone marrow sampling procedure.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
A Rice University-led research team is working on a new approach to treat acute myeloid leukemia (AML) by targeting the energy-producing mitochondria of cancer cells. By disrupting mitochondrial function, the researchers aim to selectively kill AML cells while leaving healthy blood cells unharmed.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
Researchers have developed a new treatment combining venetoclax and inobrodib that shows promising results in killing B-ALL cells, potentially reducing toxic chemotherapy needs. The approach could be less toxic than current treatments and effective in all age groups.
Charles G. Mullighan, a leading leukemia researcher at St. Jude Children's Research Hospital, has been elected Fellow of the Royal Society. His work on genomic research has advanced the understanding and treatment of acute leukemia in children.
Researchers at A.C.Camargo Cancer Center developed a more powerful version of CAR-T cells by inhibiting the epigenetic alterations that made them inefficient against non-Hodgkin's lymphoma and acute lymphoblastic leukemia. This modification resulted in improved treatment efficacy, tumor elimination, and reduced side effects.
A new study published in Genes & Diseases journal introduces a novel therapeutic approach for acute myeloid leukemia (AML) using the METTL3 degrader ZW27941. The research team found that ZW27941 exhibited potent anti-leukemic activity and synergistic effects with existing AML therapies.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A study by UC San Francisco found that children with ALL living in mixed middle- and low-income neighborhoods have a 30-40% higher risk of death. In contrast, AML hospital treatments are shorter, and outpatient visits fewer, reducing challenges for underserved patients.
Researchers discover a link between gut health and blood cancer risk, finding that age-related gut changes can accelerate the growth of pre-leukemic blood cells. A specific bacterial sugar, ADP-heptose, plays a key role in this process, and a new blood test detects its activity.
Dr Ari Melnick brings extensive experience to the institute, with a focus on precision medicine and haematological diseases. He aims to accelerate innovative treatments and enhance patient outcomes through strong partnerships with leading hospitals and research centres.
A case of therapy-related B-lymphoblastic leukemia (B-ALL) following multiple myeloma treatment is reported, characterized by unusual surface kappa light chain expression. The diagnosis was made based on immunophenotypic analysis and next-generation gene sequencing, which revealed pathogenic mutations in KDM6A and KRAS.
Large granular lymphocytic leukemias (LGLLs) are heterogeneous groups of chronic lymphoproliferative disorders. Recent molecular insights and WHO 5th edition updates refine diagnostic precision. T-cell LGLL has favorable prognosis with immunosuppressive treatment, while NK-LGLL is indolent but requires symptomatic treatment.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
Yali Dou, a molecular biologist at Keck School of Medicine of USC, has been elected as an AAAS fellow for her groundbreaking work in understanding leukemia and cancer. Her research on mixed-lineage leukemia proteins has led to the development of potential cancer treatments and a deeper understanding of epigenetics.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Researchers have developed a new approach to improve CAR-T cell therapy effectiveness in treating B-cell Acute Lymphoblastic Leukemia. By creating a TIM-3 decoy, they aim to prevent the tumor from turning off the CAR-T cells, leading to improved anti-leukaemia effectiveness and long-term persistence.
Researchers at Northwestern University have identified a previously unobserved function of Exportin-1, a protein that promotes gene transcription and stimulates stronger gene expression. This discovery could aid in the development of new medications to stymie cancer growth without harming healthy cellular function.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
Researchers at Amsterdam UMC and Moffitt Cancer Center found that contact with CLL cells leads to an energy crisis in T cells, making them unable to proliferate. The study suggests that restoring T cell energy could significantly enhance the effectiveness of current treatments for cancer.
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The study found a significant negative impact of obesity on prognosis, particularly in patients with acute lymphoblastic leukemia and brain tumors.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
A novel study found that the TPMT∗8 allele is associated with reduced metabolism of thiopurine drugs, which can lead to toxicity. The research emphasizes the importance of understanding the function of TPMT∗8 to ensure effective pharmacogenomic testing across all ancestries.